Patents Examined by Anoop Singh
  • Patent number: 9873723
    Abstract: Methods and kits for the diagnosis of illnesses related to protocadherin 19 (PCDH 19) protein deficiency or altered PCDH 19 protein function, in particular EFMR (Epilepsy and Mental Retardation limited to Females) are provided, as well as methods and kits for the identification of a predisposition to such illnesses and methods of screening subjects to identify carriers of such illnesses and methods and kits for the therapeutic or prophylactic treatment of PCDH 19 deficiency or altered PCDH 19 protein function. Further, nucleotide and amino acid sequences corresponding to a complete PCDH19 open reading frame (ORF), mutant sequences encoding non-functional PCDH19 mRNA or altered PCDH19 mRN A are described along with transformed cells and non-human transgenic animals comprising wild-type or mutant PCDH19 ORF nucleotide sequences.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: January 23, 2018
    Assignees: The University of Melbourne, Central Adelaide Local Health Network Inc.
    Inventors: Leanne Michelle Dibbens, Ingrid Eileen Scheffer, Samuel Frank Berkovic, John Charles Mulley, Jozef Gecz
  • Patent number: 9868957
    Abstract: Compositions comprised of a population of transformed bacteria formulated for topical application to a subject are described. The population of transformed bacteria are created from a non-pathogenic bacteria and transformed to express a compound of interest for a therapeutic or a cosmetic purpose. In one embodiment, the composition is for protection of the skin from ultraviolet rays.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: January 16, 2018
    Assignee: TOPGENIX, INC.
    Inventors: Noga Qvit-Raz, Tahel Altman
  • Patent number: 9861587
    Abstract: A method for prophylactic treatment of ketosis in a calving cow, the method including orally administering to the cow within a time period of about 12 hours after calving an effective dose of from 20 to 30 g of rumen protected methionine. If the cow falls into a risk category, the cow is administered the dose of rumen protected methionine once a day on the second, third, fourth, and fifth days after calving. Also, a composition including a gelatin capsule and rumen-protected methionine contained within the gelatin capsule that may be administered to a calving cow for the prophylactic treatment of ketosis. The composition may further contain within the gelatin capsule one or more other compounds known to have efficacy on fat or glucose metabolism, such as glucose, propylene glycol, niacin, choline, chromium, calcium propionate, and glucocorticoids.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: January 9, 2018
    Inventors: James M. Rohrer, Patrick D. French, Keith F. Moritz
  • Patent number: 9855211
    Abstract: The present invention relates generally to topical compositions and methods of using the same.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: January 2, 2018
    Assignee: Novan, Inc.
    Inventors: Ryan Doxey, Adam Sabouni, Eleftherios Kougoulos, Nathan Stasko
  • Patent number: 9849077
    Abstract: Disclosed are compositions and methods for their use that include a combination of Leontopodium alpinum extract, Halidrys siliquosa extract, vegetable amino acids, niacinamide, hexylresorcinol, Pinus pinaster extract, Betula alba extract, Albizia julibrissin bark extract, hydrolyzed Candida saitoana extract, Lentinus edodes mycelium extract, and/or Opuntia tuna fruit extract.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: December 26, 2017
    Assignee: Mary Kay Inc.
    Inventors: David Gan, Tiffany Florence, Michelle Hines, Patricia Jacoby, Wanli Zhao, Julia Collier, Edward Chadwick, Mauricio Castro, Barbara Durkee, Daniel Ramirez
  • Patent number: 9827177
    Abstract: The invention provides antiperspirant formulations comprising a protein and an antiperspirant salt in combination with a cosmetically acceptable carrier, together with methods of making and using these complexes and compositions.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 28, 2017
    Inventors: Shaotang Yuan, Long Pan
  • Patent number: 9822380
    Abstract: A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene can be regulated by the transcription regulation sequence; a method for production of a cell showing an inhibited replication of a human immunodeficiency virus therein, the method comprising the step of introducing the nucleic acid into a cell; and a method for treatment or prevention of a human immunodeficiency virus infection.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: November 21, 2017
    Assignee: TAKARA BIO INC.
    Inventors: Hideto Chono, Kazuya Matsumoto, Junichi Mineno, Ikunoshin Kato
  • Patent number: 9820489
    Abstract: The present invention relates to a liquid composition comprising: a) at least one alcohol; b) at least one hydrocarbon or hydrocarbon mixture; c) at least one peroxide agent; d) water. The compositions of the invention possess antimicrobial and enhanced sporicidal properties.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 21, 2017
    Assignee: Ecolab USA Inc.
    Inventors: Elke Lohrmann, Stefan Jaeger, Laurence Geret, Bernhard Meyer
  • Patent number: 9816059
    Abstract: A capsule composition containing a capsule and a stabilizing agent. The capsule has an oil core containing an active material and a capsule wall encapsulating the oil core. The active material is a fragrance, a flavor, a malodor counteractant, or a combination thereof. The wall is formed of polyurea or polyurethane. The capsule composition has 20 ppm or greater of the stabilizing agent, which is a multi-functional amine, an amino acid, a polymer mixture, or a combination thereof. Also disclosed is a consumer product containing this capsule composition.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: November 14, 2017
    Inventors: Volkert de Villeneuve, Djurre Sijbren Postma, Elizabeth Geertruida Maria Brundel, John Brahms, Li Xu, Joan G. L. Pluter, Laura French, Yabin Lei, Lewis Michael Popplewell, Xiao Huang
  • Patent number: 9802064
    Abstract: The present invention relates to a microcapsule containing a glycoprotein derived from plants. Also, the present invention provides a microcapsule having oxidation ability and which is easy to prepare. Through said antioxidant capacity, oxidation and decomposition of an internally contained material can be prevented. According to the microcapsule of the present invention, the active components, in a form which was previously stabilized by a synthetic polymer derived from crude oil or by a surfactant, can be stabilized by naturally derived components. Also, since an organic solvent is not additionally used during the capsule preparation process, the preparation is simple and eco-friendly.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: October 31, 2017
    Inventors: Hyung Jun Lim, Han Byul Kim, Do Hoon Kim, Song Seok Shin, Young Ho Park
  • Patent number: 9801916
    Abstract: Antiseptic pharmaceutical composition useful for the treatment of painful lesions in oral mucosa, ulcerative and inflammatory lesions of different origin and the treatment and/or prevention of oral mucositis and stomatitis.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: October 31, 2017
    Inventor: Tomás Bernardo Galvan Gonzalez
  • Patent number: 9790489
    Abstract: The present invention provides a method and components thereof of performing genetic modification under a drug-free environment. The method comprises the steps of generating a trapped mammalian cell library by trapper constructs (including the element of piggyBac terminal inverted repeats (TIRs)), reporter constructs, and helper constructs (including a sequence of an internal ribosomal entry site (IRES)). The present art allows: (1) to target & identify the silenced loci; (2) to separate genes with low-level expression at certain differentiation stages; (3) to evaluate the efficiency of gene targeting in the silent or repressed loci. The present invention avoids the biased gene targeting observed in the prior arts, and eliminates the needs of introducing antibiotic genes into the host genome which may lead to a potential threat of drifting antibiotic resistant genes into environment.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: October 17, 2017
    Inventors: Yaa-Jyuhn James Meir, Chiung-Yuan Sareina Wu, Herng-Shing Yang
  • Patent number: 9765082
    Abstract: A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-193° C. determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90<10 ?m. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 ?m, preferably 1 to 6 ?m, more preferably 1.5 to 5 ?m.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: September 19, 2017
    Assignee: EUTICALS SPA
    Inventors: Paride Grisenti, Maria Argese, Roberto Scrocchi, Alessandro Livieri, Giuseppe Guazzi
  • Patent number: 9752128
    Abstract: The present invention relates to cellular differentiation and, in particular to hybrid cells that exhibit phenotypic plasticity and methods for producing these cells. The invention also relates to methods for generating specific cells of a desired phenotype. The invention still further relates to methods of producing hybrid cells with a capacity to de-differentiate into an earlier progenitor state. The invention further contemplates the use of hybrid cells in a range of applications, for example tissue generation.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: September 5, 2017
    Assignee: Stephen Sanig Research Institute Ltd.
    Inventors: Galina Kaseko, Tohsak L. Mahaworasilpa
  • Patent number: 9730435
    Abstract: Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 15, 2017
    Inventors: John McWhirter, Cagan Gurer, Lynn Macdonald, Andrew J. Murphy
  • Patent number: 9730871
    Abstract: A solid or soft solid antiperspirant/deodorant composition comprising at least one antiperspirant or deodorant active, a base component in an amount of from 2% and 15% by weight of the composition, wherein the base component is C8 to C14 fatty acid in free acid form, and a gellant, wherein the gellant comprises less than 50% by weight of the gellant stearyl alcohol. The C8 to C14 fatty acid in free acid form can be lauric acid. The C8 to C14 fatty acid in free acid form provides antibacterial properties to the compositions.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: August 15, 2017
    Inventors: Aixing Fan, Edward Simpson, Joanna Wu, James G. Masters
  • Patent number: 9732323
    Abstract: The present invention describes an efficient and rapid protocol to generate hepatocyte cells from human induced pluripotent stem cells (iPSCs). According to the method, the iPS cells can be differentiated into functional hepatocyte cells in a short time course (less than 15-20 days). The iPSC-derived hepatocyte cells of the invention have a similar gene expression profile to mature hepatocytes. Moreover, the iPSC-derived hepatocyte cells is proved to rescue lethal fulminant hepatic failure in a non-obese diabetic severe combined immunodeficient mouse model. The rapid and efficient differentiation protocol for generation of iPSC-derived hepatocyte cells may offer an alternative option for treatment of liver diseases.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 15, 2017
    Inventors: Oscar Kuang-Sheng Lee, Yu-Fan Chen, Chien-Yu Tseng
  • Patent number: 9717666
    Abstract: The invention relates to a skin lightening composition, more particularly a composition which derives synergy between an active of natural origin and an active of synthetic origin. The present inventors have judiciously combined a selective salt of a dicarboxylic acid viz. disodium fumarate along with a specific extract of a plant source e.g. Salvia officinalis rich in certain organic aromatic acids to provide for synergic skin lightening benefits. They have further found that inclusion of certain activity enhancers in the composition of the invention improves the skin lightening efficacy.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: August 1, 2017
    Assignee: Conopco, Inc.
    Inventors: Punam Bandyopadhyay, Sujeetkumar Jha, Shilpa Atul Vora, Anita Damodaran
  • Patent number: 9718839
    Abstract: The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 1, 2017
    Assignees: SYMRISE AG, BASF SE
    Inventors: Thomas Subkowski, Michael Backes, Heiko Oertling, Arnold Machinek, Hubert Loges, Ulrike Simchen, Horst Surburg, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel
  • Patent number: 9708635
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: July 18, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela